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ABSTRACT.
Purpose: Patients with proliferative diabetic retinopathy (PDR) treated with
panretinal photocoagulation (PRP) can have abnormal visual functioning that
may be missed by Snellen visual acuity alone. We investigated reading deficits in
patients treated with PRP for PDR using the Minnesota reading (MNREAD)
test.
Methods: Thirty patients treated with PRP and 15 controls underwent best-
corrected visual acuity (BCVA), the MNREAD, frequency doubling perimetry
(FDP), and fundus photography. Panretinal photocoagulation (PRP)-treated
subjects were compared to controls on MNREAD results by two-sample t-tests
and Wilcoxon tests and Pearson correlations were used to assess the association
between performance on MNREAD and other central visual function tests within
PRP subjects.
Results: Panretinal photocoagulation (PRP)-treated patients had reduced
MNREAD acuity (p < 0.0001) and increased critical print size (p = 0.01)
compared to controls but not a significantly reduced maximum reading speed
(p = 0.06). Logmar MNREAD acuity was strongly positive correlated with
logMAR BCVA (r = 0.58, p = 0.0098) and strongly negatively correlated with
FDP foveal threshold (r = 0.63, p = 0.0030). Maximum reading speed was
positively correlated with FDP foveal threshold (r = 0.57, p = 0.0143) and FDP
mean deviation (r = 0.51, p = 0.0432). Visual acuity did not correlate with the
sensitivities on the FDP.
Conclusion: The MNREAD test reveals that PRP reduces reading ability and
other aspects of macular function, and thus provides new understanding of how
vision-related quality of life is impaired. These findings may lead to improved
means to evaluate and enhance vision following treatment for PDR.
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(PDR) is characterized by retinal neo-
vascularization (Duh et al. 2017), and
its treatment commonly includes pan-
retinal photocoagulation (PRP) (Mar-
tinez-Zapata et al. 2014; Bressler et al.
2017; El Rami et al. 2017). Treatment
outcomes are typically evaluated based
on central visual acuity (VA) (Stewart
2016), but other measures of visual
function (Spreng et al. 2018), including
tests of contrast sensitivity, reading
ability, visual field sensitivities and
vision in dim light conditions provide
more comprehensive information
about macular function (Boynton et al.
2015). As such, patients often feel their
reduced vision negatively impacts their
quality of life (QOL), which may be
overlooked when vision assessment is
based on acuity alone. Recent gene
therapy studies have demonstrated the
ability to restore central vision in
persons with advanced retinal degener-
ation (Bainbridge et al. 2015; Russell
et al. 2017). Eyes treated with PRP
exhibit reduced peripheral and macular
function and fundus lesions similar to
those in eyes with retinitis pigmentosa.
Similar future efforts to improve vision
in persons who have undergone PRP
will require comprehensive measures of
visual function and impact on the QOL
to determine successful responses to
therapy.
Reading charts have been used to
quantify central visual function for
retinitis pigmentosa, macular degener-
ation and glaucoma (Virgili et al. 2004;
Ishii et al. 2013; Radner 2017; Vara-
daraj et al. 2018). Unlike Snellen VA
charts that use single letter optotypes,
reading charts provide more informa-
tion on visual function by using sen-
tences in a logarithmic scale. In
addition to the reading acuity, reading
tests provide the maximum reading
speed and the critical print size that
can assess the ease with which patients
can read. Previous studies have also
correlated reductions in reading speeds
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with reduced sensitivity on
microperimetry (Edington et al. 2017),
suggesting that reading tests uncover
other aspects of visual dysfunction.
Moreover, reading is more representa-
tive of the impact of vision on the QOL
than Snellen VA, because it reflects real
world function in patients with macu-
lar pathologies (Jackson & Owsley
2003; Kanonidou 2011). It also tests
vision at a different distance than
standard Snellen VA. To our knowl-
edge, reading ability as measured by
the Minnesota reading (MNREAD)
test has not been evaluated on persons
who have undergone PRP.
Boynton et al. (2015) initially
described this cohort’s performance
on a variety of visual function tests in
comparison with non-diabetic controls.
Over two-thirds of the patients had a
VA of 20/20 or better but severe deficits
on photopic visual fields and dark-
adaptation testing. Furthermore, many
patients at follow-up have admitted
that they gave up reading due to their
retinopathy. Therefore, it is apparent
that Snellen VA does not adequately
describe visual function related QOL in
this cohort. In this analysis, we inves-
tigated both the performance on the
MNREAD in the PRP-treated subjects
compared to controls and the relation-
ship between results of the MNREAD
test with other deficits of macular
visual functioning in PRP-treated sub-
jects. Our central hypothesis is that
PRP-treated subjects will have a signif-
icantly reduced performance on the
MNREAD (as manifested by a
reduced reading acuity, slower maxi-
mum reading speed, and larger critical
print size) compared to controls. We
also predicted that the reduction in
MNREAD parameters would correlate
with reductions on other macular func-
tion tests such as Snellen VA and
sensitivity on the frequency doubling
perimetry (FDP).
Materials and Methods
This study was conducted at the
University of Michigan W. K. Kellogg
Eye Center. The study adhered to the
tenets of the Declaration of Helsinki,
and was approved by the University of
Michigan Medical School Institutional
Review Board (HUM 60596). Diabetic
patients with PDR treated by PRP and
age-matched controls were enrolled
into the study after a screening visit in
the retina clinic. Signed informed con-
sent was acquired from all participants
before research testing.
Patient enrollment and evaluation
Subject enrollment and the eligibility
criteria were the same as the study by
Boynton et al. (2015). Briefly, the PRP
study group enrolled adultswith type 1or
2 diabetes mellitus who had PDR treated
withPRPat least 6 months before enroll-
ment into the study. Inclusion criteria for
the study group were the following: (1)
age ≥18 years old; (2) diabetes mellitus as
defined by the American Diabetes Asso-
ciation diagnostic criteria; (3) treatment
of PDR by PRP ≥ 6 months prior to
enrollment; (4) stable PDRafter the PRP
treatment; and (5) best-corrected visual
acuity (BCVA) of 20/400 or better in the
study eye. If both eyes were eligible, the
one with the worst BCVA was chosen as
the study eye.
Exclusion criteria for the PRP study
group were the following: (1) any
retinal or ocular disease other than
PDR; (2) any significant cystoid mac-
ular oedema; (3) any high-risk ocular
neovascularization; (4) history of drug
or alcohol abuse; (5) any neurologic or
systemic disease that could impair
vision, other than diabetes; (6) any
systemic or ocular medication that
could affect vision; (7) hospitalization
within 1 month of screening; (8) differ-
ence in two recent consecutive haemo-
globin A1c measurements ≥5%; (9)
unable to give informed consent or
unable to complete testing; (10) spher-
ical equivalent > 6.00 dioptres; (11)
pregnant or nursing; (12) blood pres-
sure ≥ 180/100 mmHg.
The study also enrolled 15 age-
matched controls enrolled as volunteers.
Inclusion and exclusion criteria were the
same for controls, except that they had
no condition that could affect vision.
All subjects underwent a compre-
hensive ophthalmologic examination
including a slit lamp exam and dilated
fundus exam with a 90 D lens (per-
formed by T.W.G). Age and demo-
graphic data were taken to allow age
matching for comparisons between
groups. Medical and ocular histories
were taken to ensure that subjects met
enrollment criteria and that we knew
the type and duration of diabetes in
PRP subjects. Optimal refraction was
assessed manually using the phoropter,
and measurement of BCVA was done
using the electronic VA tester with
Snellen chart line testing. LogMAR
VA was recorded and used for statis-
tical analysis. A blood sample was
obtained from each participant to mea-
sure glycosylated haemoglobin
(HbA1c) levels if they had not been
measured within the last 6 months.
If patients were eligible and consent
was given, screening was completed
and patients returned for a study visit.
During this visit, functional vision tests
were performed in the same order,
which included MNREAD testing and
FDP. Phenotyping included fundus
photography.
Minnesota reading test
The MNREAD test is performed with
a single reading card that contains
multiple 10-word text phrases, each in
different font sizes, and with the char-
acters and lines equally spaced. The
largest font size of a phrase corre-
sponds to a Snellen line of 20/400 and
the smallest font size corresponds to a
Snellen line of 20/06. Subjects under-
went MNREAD testing in a designated
room where light intensity was cali-
brated to standard room light condi-
tions at a luminescence of around
100 cd/m2. The reading card was
placed 40 cm from the subject and
vision was corrected to that distance.
Subjects read aloud progressively smal-
ler MNREAD text phrases starting at
20/400, and decreasing in logMAR
increments of 0.1, using only the
study eye. While subjects read a phrase,
the other phrases were blocked out so
that they could not read ahead. The
amount of time to read each phrase
was recorded, as well as the number of
words read correctly and incorrectly.
Different MNREAD cards were used
based on whether the study eye was a
right or left eye. All the characteristics
of the cards were the same, but the
letters had a different orientation.
Three variables were calculated from
testing results: the MNREAD testing
acuity, maximum reading speed, and
the critical print size. The MNREAD
testing acuity was determined as the
phrase with the smallest font size where
a patient could read all the words, even
if they read some of them incorrectly. If
the subject did not read any of the
words correctly, then we recorded the
MNREAD acuity as the phrase above.
The reading speed for a standard 10-
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The maximum reading speed was
deduced as the fastest speed at which
the patient could read of all the lines
that were successfully read.
The critical print size was the
MNREAD phrase with the smallest
font that the patient could read at the
maximum reading speed. The font size
was converted to a corresponding Snel-
len VA line that is automatically com-
puted on the MNREAD reading cards.
The critical print size served as a surro-
gate for the minimum size of the letters
that the patient can read at the maxi-
mum reading speed, thereby indicating
the ease with which subjects can read.
FDP
Participants performed FDP with the
24-2 protocol using the Matrix perime-
ter (Carl Zeiss Meditec, Dublin, CA,
USA). The reliability criteria used were
<33% fixation errors, <33% false pos-
itive errors, and <33% false negative
errors. The FDP 24-2 strategy was
performed on the Humphrey Matrix
715 Visual Field Analyzer (Zeiss,
Oberkochen, Germany). The stimulus
was 0.25 cycles per degree monochrome
sinusoidal grating of vertical grey
stripes that was phase reversed at
18 Hz (Leeprechanon et al. 2007; Jolti-
kov et al. 2017). The minimum contrast
threshold of the 5° diameter stimulus
was measured at each of 55 test loca-
tions (Joltikov et al. 2017). The testing
time was approximately 5 min per eye.
Subjects wore their own distance pre-
scription glasses if needed. Foveal sen-
sitivity, mean deviation (MD), and
pattern standard deviation (SD) were
recorded. Foveal sensitivity represents
the minimum intensity of the stimulus
at the fovea required for a patient
response. Pattern SD measures local-
ized deficits by factoring out general-
ized reductions in sensitivity.
Fundus photographs
A 200-degree colour photograph cen-
tred on the macula was taken of each
study eye using a non-simultaneous
stereoscopic, on-axis, non-steered, 200°
ultrawide field imaging on the Optos
camera (Optos, Dunfermline, UK).
Statistical analysis
Descriptive statistics were used to sum-
marize patient demographics, clinical
measures of the study eye, tests of
macular function and MNREAD test-
ing performance, for the PRP study
subjects and controls. Differences
between PRP study subjects and con-
trols were tested with two-sample t-
tests and Wilcoxon tests for continuous
measures, and with chi-square and
Fisher’s exact tests for categorical mea-
sures. Within the PRP study group,
scatterplots and Pearson’s correlations
(r) were used to assess the association
between performance on MNREAD
testing with other visual function
parameters. All measures of VA were
converted to LogMAR (Holladay
1997) for analysis. p-values were
adjusted for multiple comparisons with
the Holm method. Associations were
considered statistically significant when
p-value <0.05. All statistical analyses
were performed using SAS version 9.4
(SAS Institute, Cary, NC, USA).
Results
Thirty study patients who had PRP to
treat their PDR and 15 age-matched,
healthy controls were enrolled in this
study. Table 1 compares the demograph-
ics of the PRP and control subjects.
Panretinal photocoagulation (PRP)
patients and controls were age-matched
(mean  SD; 58.6  13.4 and 59.8 
17.8 years, respectively; p = 0.79) and
had a similar gender distribution (both
60% male, p = 1.00). Groups were sim-
ilar with respect to intraocular pressure
(PRP group: 15.7  2.8 mmHg; control
group: 15.0  3.7 mmHg; p = 0.46).
The PRP-treated group had higher hae-
moglobin A1C (7.4%  1.2 versus 5.5%
 0.3, respectively) and a worse VA
(0.17  0.19 LogMAR units versus
0.08  0.10 LogMAR units, respec-
tively, as measured by Snellen). The
PRP-treated group had an average dia-
betes duration of 36.3 years (SD = 12.6)
and their PRP was an average of
13.3 years prior to testing (SD = 8.6),
consistentwith their inactive retinopathy.
MNREAD
Panretinal photocoagulation (PRP)-
treated subjects had worse performance
on the MNREAD test than controls for
two of the three MNREAD testing
measures (Table 2). The PRP group
had significantly worse MNREAD acu-
ity (p < 0.0001), corresponding to a
Snellen acuity of 20/32 versus 20/20 for
controls. There was also an increase in
the critical print size for PRP-treated
subjects compared to controls (p = 0.01),
corresponding to a Snellen letter size of
20/200 for PRP subjects and 20/100 for
controls. Although on average PRP-
treated subjects exhibited reduced read-
ing speed relative to controls, the differ-
ence was not statistically significant
(157.1  30.0 versus 170.9  18.1
Table 1. Descriptive statistics summarizing the differences between the PRP and control subject
samples.
PRP group (n = 30) Control group (n = 15)
p-value*# (%) # (%)
Male 18 (60) 9 (60) 1.0
Female 12 (40) 6 (40)
Mean (SD) Mean (SD)
Age (years; SD) 58.6 (13.4) 59.8 (17.8) 0.80
Duration diabetes mellitus (years) 36.3 (12.6) NA NA
Years Since PRP 13.3 (8.6) NA NA
Haemoglobin A1C (%) 7.4 (1.2) 5.5 (0.3) 0.0001
LogMAR Snellen visual acuity 0.17 (0.19) 0.08 (0.10) 0.0001
IOP (mm Hg) 15.7 (2.8) 15.0 (3.7) 0.46
ETDRS = Early Treatment Diabetic Retinopathy Study, IOP = intraocular pressure,
PRP = panretinal photocoagulation, SD = standard deviation.
* Two-sample t-test for age, IOP, LogMAR visual acuity; two-sample Wilcoxon test for
haemoglobin A1C; chi-square test for gender.
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characters/second, respectively, p =
0.06). Collectively, these results reveal
significant impairment of reading ability
in the PRP-treated individuals.
FDP
Table 2 also contains central visual
field testing results on the FDP in
PRP and control groups. Panretinal
photocoagulation (PRP)-treated sub-
jects showed reduced foveal threshold
(22.1  7.4 dB versus 30.0  5.1 dB;
p < 0.0001), and reduced MD on the
FDP 24-2 (8.20  5.76 dB versus
1.09  2.52 dB; p < 0.0001).
Correlations between MNREAD and
other functional parameters
Table 3 and Fig. 1 summarize the
association between performance on
MNREAD testing and other central
visual function tests in PRP-treated
subjects. The logMAR reading acuity
was significantly correlated with
performance on central vision tests.
Specifically, a strong positive correla-
tion was noted with logMAR Snellen
VA (r = 0.58, p = 0.0007), and strong
negative correlations were noted with
FDP foveal threshold (r = 0.63,
p = 0.0002). The maximum reading
speed correlated positively with the
performance on FDP foveal threshold
(r = 0.57, p = 0.0011), and FDP 24-2
MD (r = 0.51, p = 0.0036). The Snel-
len VA did not correlate with either the
FDP foveal threshold or FDP MD.
The critical print size correlated only
with Snellen logMAR VA (r = 0.47,
p = 0.0085), but this finding was not
significant after adjustment for multi-
ple comparisons (adjusted p = 0.093).
Discussion
Our study shows for the first time
that PRP-treated patients have
reduced reading performance on the
MNREAD compared to controls.
Although these deficits are expected
due to a slightly worse VA in the
PRP-treated group, the MNREAD
test provides more information on
central visual function than standard
Snellen VA. First, the MNREAD
assesses performance on a task that
many patients with macular diseases,
such as age-related macular degenera-
tion, have difficulty with and believe is
important for their QOL (Patel et al.
2011). The reading speed and critical
print size yield more information
about how easy or difficult subjects
find reading. There were many exam-
ples of patients who read on the same
acuity line but had very different
reading speeds and critical print sizes
(Fig. 2), suggesting that they have
different levels of difficulty with read-
ing. Furthermore, the deficits on
MNREAD testing were associated
with multiple deficits in central visual
functioning, including VA, FDP MD,
and FDP foveal threshold. The Snel-
len VA, however, did not have signif-
icant correlations with FDP
sensitivities, suggesting that the
MNREAD provides more informa-
tion about global macular function-
ing. We advise clinicians to counsel
patients undergoing PRP that they
may experience difficulties with read-
ing over time.
Notable strengths of this study are
that we were able to detect significant
reading deficits in PRP-treated subjects
as compared to controls, and show that
this test provides more information
about visual functioning than standard
Snellen VA alone. Weaknesses of this
study include the small number of
subjects, which may explain why max-
imum reading speed was not signifi-
cantly reduced. Also, we did not have






p-value*Mean (SD) Mean (SD)
logMAR reading acuity 0.23 (0.27) 0.05 (0.05) 0.0001
Maximum reading speed
(characters/second)
157.1 (30.0) 170.9 (18.1) 0.062
LogMAR critical print size 0.98 (0.26) 0.75 (0.32) 0.013
FDP foveal sensitivity (decibels) 22.1 (7.4) 30.0 (5.1) 0.0002
FDP 24-2MD (decibels) 8.20 (5.76) 1.09 (2.52) 0.0001
FDP = frequency doubing perimetry, MD = mean deviation, PRP = panretinal photocoagula-
tion, SD = standard deviation.
* Two-sample t-test for maximum read speed and LogMAR critical print size; two-sample
Wilcoxon test for LogMAR reading acuity. Two-sample Wilcoxon test for FDP foveal sensitivity
and FDP MD.
Table 3. Correlation between performance on MNREAD and other visual function parameters, within PDR subjects treated with PRP (n = 30).
LogMAR Snellen VA FDP foveal threshold (dB) FDP 24-2 MD (dB)
LogMAR MNREAD acuity 0.58
(p = 0.0007)
(adj p = 0.0098)
0.63
(p = 0.0002)
(adj p = 0.003)
0.43
(p = 0.0166)
(adj p = 0.1149)




(adj p = 0.4165)
0.57
(p = 0.0011)
(adj p = 0.0143)
0.51
(p = 0.0036)
(adj p = 0.0432)
LogMAR MNREAD critical print size 0.47
(p = 0.0085)
(adj p = 0.0935)
0.02
(p = 0.9283)
(adj p = 1.0000)
0.09
(p = 0.6505)
(adj p = 1.0000)
The correlation coefficient is listed with the p-value in parentheses. p-values adjusted for multiple comparisons by the Holm method are also provided.
Statistically significant associations are highlighted in bold.
FDP = frequency doubling perimetry, MD = mean deviation, MNREAD, Minnesota Reading Test, PDR = proliferative diabetic retinopathy,
PRP = panretinal photocoagulation, VA = visual acuity.
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patients with PDR but no panretinal
photocoagulation as a control to com-
pare the effects of PRP alone. How-
ever, all of the PRP patients had
quiescent retinopathy, so this is unli-
kely to have had an effect on the results
of our study. Another limitation was
the heterogeneity in both the length of
time that patients had diabetes, and the
number of years after they had PRP.
We did not find any significant associ-
ations between any MNREAD param-
eters and either age or duration of
diabetes. However, the number of years
since PRP was negatively correlated
with the maximum reading speed
(r = 0.605, p = 0.002) but not with
logMAR MNREAD acuity.
Clinical trials for diabetic retinopa-
thy (Cai & Bressler 2017) and retinal
dystrophies (Neto et al. 2017; Schatz
et al. 2017) employ endpoints for
Fig. 1. Scatterplots displaying the relationship between performance on the Minnesota reading test and tests of central visual function, within
proliferative diabetic retinopathy subjects treated with panretinal photocoagulation (n = 30).
Fig. 2. Two panretinal photocoagulation (PRP) patients with the same Minnesota reading acuity
and similar appearance of the macula on fundus photo. However, PRP treated subject 2 has a
significantly reduced reading speed and increased critical print size as compared to PRP treated
subject 23, suggesting that PRP subject 2 has much more difficulty with reading.
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central vision function aimed at pre-
serving and/or improving Snellen VA,
but patients may have multiple visual
function deficits that are missed when
Snellen VA is used alone. Therefore, in
developing future clinical trials to
improve or restore central visual func-
tion for thosewith PDR treated by PRP,
more comprehensive measures to quan-
tify improvement and vision-related
QOL are needed. Reading tests like the
MNREAD may provide another end-
point for measuring visual function in
therapeutic trials. Furthermore, reading
tests may easily be integrated into clin-
ical practice as an objective measure of
central visual function.
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